MedTrace Logo

Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma

NCT05476965 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-07-27

No results posted yet for this study

Summary

This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the subject's cancer, then de-escalation radiotherapy can be used.

Conditions

Interventions

COMBINATION_PRODUCT

induction therapy; surgery; radiotherapy

Radiotherapy: de-escalation radiotherapy or standard radiotherapy

Sponsors & Collaborators

  • Hubei Cancer Hospital

    lead OTHER

Principal Investigators

  • Desheng Hu, Dr. · Hubei Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476965 on ClinicalTrials.gov